Atrial fibrillation in patients with liver disease: Recent advances

Area of Science:

• Cardiology
• Hepatology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a growing global health concern linked to increased morbidity and mortality.
• Ischemic stroke is a primary complication of AF, typically managed with oral anticoagulants.
• Hepatic impairment, often due to non-alcoholic liver disease, complicates AF management.

Approach:

• This review synthesizes current evidence on anticoagulation strategies for patients with atrial fibrillation and liver disease.
• It examines the challenges posed by altered coagulation and drug metabolism in hepatic impairment.
• The focus is on balancing stroke prevention with bleeding risk in this vulnerable patient group.

Key Points:

• Anticoagulation in liver disease is challenging due to altered coagulation pathways and increased bleeding risk.
• Monitoring anticoagulation (e.g., INR) is complicated by spontaneous elevations, altered drug metabolism, and thrombocytopenia.
• Risk factor management is crucial for optimizing anticoagulation in patients with AF and liver disease.

Conclusions:

• The risk of ischemic stroke in patients with atrial fibrillation and liver disease often outweighs the risk of major bleeding.
• Careful consideration of individual patient factors and risk stratification is essential.
• Further research may be needed to refine anticoagulation protocols for this complex population.